# US 11,439,687 B2 · Blood plasma fractions for use in muscle regeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,439,687 B2
- Document ID: US11439687B2
- Status: Granted
- Kind: B2
- Application number: 17/087,898
- Filed: 2020-11-03
- Published: 2021-05-06
- Granted: 2022-09-13
- Earliest claimed: 2019-11-04
- Assignees: Alkahest, Inc.
- Applicants: Alkahest, Inc.
- Inventors: Viktoria Kheifets; Benson Lu; Annette Tennstaedt
- Web page: https://patentgrep.com/patent/US11439687B2

## CPC

- A61K 38/38: Albumins
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 38/385: {Serum albumin}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for treating aging-related diseases as well as muscle recovery, prevention of muscle degeneration, and maintenance of muscle are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.

## Claims

### Claim 1

A method of improving muscle regeneration thereby reducing symptoms of a muscle disorder in a subject diagnosed with the muscle disorder, the method comprising administering an effective amount of a Plasma Fraction to the subject wherein the Plasma Fraction is a Plasma Protein Fraction (PPF) containing between 83% and 95% albumin, no more than 17% globulin and no more than 1% gamma globulin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the administering is performed using a Pulse Dose dosing regimen.

### Claim 3 (depends on 1)

The method of claim 1 wherein the muscle disorder resulted from acute injury.

### Claim 4 (depends on 1)

The method of claim 1 wherein the muscle disorder is a dystrophy.

### Claim 5 (depends on 4)

The method of claim 4 wherein the dystrophy is selected from the group consisting of Duchenne and Becker muscular dystrophy, myotonic dystrophy, limb girdle muscular dystrophy, Emery-Dreifuss muscular dystrophy, congenital muscular dystrophy, and facioscapulohumeral muscular dystrophy.

### Claim 6 (depends on 1)

The method of claim 1 wherein the muscle disorder is selected from the group consisting of muscle atrophy, muscle weakness, McArdle disease, muscle weakness associated with stroke, degeneration associated with amyotrophic lateral sclerosis, neuromuscular junction disorders, myasthenia gravis, toxic myopathy, inflammatory myopathy, lipid storage myopathy, ischemia, and contraction-induced damage.

### Claim 7 (depends on 1)

The method of claim 1 wherein the muscle disorder is acute muscle injury resulting from sports activity.

### Claim 8 (depends on 1)

The method of claim 1 wherein reducing symptoms of the muscle disorder comprises eliminating symptoms of the muscle disorder.